<DOC>
	<DOCNO>NCT02308748</DOCNO>
	<brief_summary>The primary objective research study test hypothesis late sodium current blocking drug ( mexiletine lidocaine ) attenuate effect hERG potassium channel block drug ( dofetilide ) ventricular repolarization ( QTc ) shorten early repolarization ( J-Tpeakc ) . The secondary object ass ability calcium channel block ( diltiazem ) reduce QTc prolongation associate hERG block ( moxifloxacin ) .</brief_summary>
	<brief_title>Ability Late Sodium Calcium Current Block Balance ECG Effects Potassium Current Block</brief_title>
	<detailed_description>This randomize , double-blind , 5-period crossover study healthy male female subject , 18 35 year age , compare electrophysiological response hERG potassium channel block drug without addition late sodium calcium channel block drug . The 5 treatment period 1 ) dofetilide alone , 2 ) mexiletine without dofetilide , 3 ) lidocaine without dofetilide , 4 ) moxifloxacin without diltiazem 5 ) placebo . During treatment period , 12 blood sample pharmacokinetic measurement obtain match 12-lead ECG recording .</detailed_description>
	<mesh_term>Long QT Syndrome</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Dofetilide</mesh_term>
	<mesh_term>Mexiletine</mesh_term>
	<mesh_term>Diltiazem</mesh_term>
	<mesh_term>Moxifloxacin</mesh_term>
	<mesh_term>Fluoroquinolones</mesh_term>
	<mesh_term>Norgestimate , ethinyl estradiol drug combination</mesh_term>
	<criteria>1 . Subject healthy man woman , 18 35 year age , inclusive , weigh least 50 kg ( 110 pound ) , 85 kg ( 197 pound ) body mass index 18 27 kg/m2 , inclusive , Screening . 2 . Subject normal medical history finding , clinical laboratory result , vital sign measurement , 12 lead ECG result , physical examination finding Screening , abnormal , abnormality consider clinically significant ( determine document investigator designee ) . 3 . Male female subject must agree practice 2 highly effective method birth control ( determine investigator designee ; one method must barrier technique ) Screening 30 day last dose study drug . 1 . Subject 12 lead safety ECG result Screening Check Period 1 evidence follow abnormality : QT correct interval ( QTc ) use Fridericia correction ( QTcF ) &gt; 430 millisecond ( m ) PR interval &gt; 220 m &lt; 120 m QRS duration &gt; 110 ms Second thirddegree atrioventricular block Complete leave right bundle branch block incomplete right bundle branch block Heart rate &lt; 50 &gt; 90 beat per minute Pathological Qwaves ( define Q wave &gt; 40 m ) Ventricular preexcitation 2 . Subject 12 ectopic beat 3 hour Holter ECG Screening . 3 . Subject history unexplained syncope , structural heart disease , long QT syndrome , heart failure , myocardial infarction , angina , unexplained cardiac arrhythmia , torsades de pointes , ventricular tachycardia , placement pacemaker implantable defibrillator . Subjects also exclude family history long QT syndrome ( genetically proven suggest sudden death close relative due cardiac cause young age ) Brugada syndrome . 4 . Subject history current evidence clinically significant ( determined investigator ) cardiovascular , dermatologic , endocrine , gastrointestinal , hematologic , hepatic , immunologic , metabolic , neurologic , psychiatric , pulmonary , renal , urologic , and/or major disease malignancy ( exclude nonmelanoma skin cancer ) . The investigator may allow exception criterion ( e.g. , stable mild joint disease [ interfere influence activity require protocol , opinion investigator ] , cholecystectomy , childhood asthma ) follow discussion medical monitor . 5 . Subject history thoracic surgery . 6 . Subject condition possibly affect study drug absorption ( e.g. , gastrectomy , Crohn 's disease , irritable bowel syndrome ) . 7 . Subject skin condition likely compromise ECG electrode placement . 8 . Subject female breast implant . 9 . Subject 's laboratory test result Screening Check Period 1 outside reference range provide clinical laboratory consider clinically significant ( determine document investigator designee ) . 10 . Subject 's laboratory test result Screening Check Period 1 indicate hypokalemia , hypocalcemia , hypomagnesemia accord low limit reference range provide clinical laboratory . 11 . Subject 's laboratory test result Screening Check Period 1 &gt; 2 × upper limit normal ( ULN ) alanine aminotransferase aspartate aminotransferase , &gt; 1.5 × ULN bilirubin , &gt; 1.5 × ULN creatinine . 12 . Subject positive test result Screening human immunodeficiency virus , hepatitis C antibody , hepatitis B surface antigen . 13 . Subject mean systolic blood pressure &lt; 90 &gt; 140 mmHg mean diastolic blood pressure &lt; 50 &gt; 90 mmHg either Screening Check Period 1 .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>